Saturday 17 October 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024. In the quarter to June 2026, revenue grew 45.4%, EPS grew 100.0%, free cash flow grew 8.47% and total debt rose 5.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
30.56
1.20
−3.78%
Follow CAI
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 22.86 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 42.50 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 1,769 | 1,846 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.23 | 0.44 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 306 | 412 | 812 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 29.17 | 43.37 | 66.40 | |||||
| EBT | — | — | — | — | — | — | — | (341) | (282) | (68) | |||||
| EBT margin, % | — | — | — | — | — | — | — | (111.53) | (68.38) | (8.38) | |||||
| Net income | — | — | — | — | — | — | — | (341) | (282) | (68) | |||||
| Depreciation | — | — | — | — | — | — | — | 54 | 56 | 35 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 8.76 | 11.61 | 4.86 | ||||
| Earnings | — | — | — | — | — | — | — | (9.77) | (7.94) | (3.22) | |||||
| Cash flow | — | — | — | — | — | — | — | (7.90) | (6.91) | 0.50 | |||||
| Capex | — | — | — | — | — | — | — | (0.64) | (0.24) | (0.10) | |||||
| Free cash flow | — | — | — | — | — | — | — | (8.54) | (7.15) | 0.40 | |||||
| Book value | — | — | — | — | — | — | — | 0.00 | (70.40) | 3.45 | |||||
| Shares, m | — | — | — | — | — | — | — | 35 | 35 | 167 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 5.56 | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 7.81 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 5.04 | |||||
| EV/FCF | — | — | — | — | — | — | — | (4.55) | (4.55) | 61.14 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (276) | (245) | 83 | ||||
| Capex | — | — | — | — | — | — | — | (22) | (8) | (16) | |||||
| Free cash flow | — | — | — | — | — | — | — | (298) | (254) | 67 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 50 | 871 | ||||
| Total debt | — | — | — | — | — | — | — | — | 380 | 379 | |||||
| Net debt | — | — | — | — | — | — | — | — | 312 | (421) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (2,499) | 577 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (220.09) | (73.22) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 18.05 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 0.00 | 55.99 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Caris Life Sciences,�Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech, Inc. | $9.8B | 38.3× | 38.6× | +24.14% (above 0%: growing) | +39.10% (above 0%: growing) | +40.14% (above 0%: growing) | 94.60% | 49.00% | Compare |
| KYMR Kymera Therapeutics, Inc. | $9.0B | — (loss-making) | — (loss-making) | +466.40% (above 0%: growing) | n/m | +9.97% (above 0%: growing) | 100.00% | (116.32%) | Compare |
| CAI Caris Life Sciences,�Inc. | $9.0B | 81.3× | 163× | +45.38% (above 0%: growing) | n/m | +8.47% (above 0%: growing) | 68.10% | 10.21% | |
| CYTK Cytokinetics, Incorporated | $8.9B | — (loss-making) | — (loss-making) | −57.13% (below 0%: shrinking) | n/m | −24.02% (below 0%: shrinking) | 80.46% | (625.95%) | Compare |
| PTGX Protagonist Therapeutics, Inc. | $8.8B | 106× | 25.0× | +3,749.17% (above 0%: growing) | n/m | +839.65% (above 0%: growing) | 100.00% | 74.37% | Compare |
| TGTX TG Therapeutics, Inc. | $8.6B | 17.8× | 29.4× | +70.27% (above 0%: growing) | −73.68% (below 0%: shrinking) | +427.05% (above 0%: growing) | 82.86% | 9.02% | Compare |
| AXSM Axsome Therapeutics, Inc. | $8.5B | — (loss-making) | — (loss-making) | +45.54% (above 0%: growing) | n/m | −2.98% (below 0%: shrinking) | 93.79% | (22.73%) | Compare |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.3B | — (loss-making) | — (loss-making) | +171.02% (above 0%: growing) | n/m | −15.43% (below 0%: shrinking) | 100.00% | (226.03%) | Compare |
| ABVX Abivax SA Sponsored ADR | $8.1B | — (loss-making) | — | — | n/m | −48.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $8.7B | 38.3× | 29.4× | +70.27% | — | +3.49% | 94.20% | (11.36%) |
Caris Life Sciences,�Inc. (CAI) key facts
- Strength: Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Caris Life Sciences,�Inc. (CAI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CAI traded at $30.56, a market capitalization of $9.0 billion.
- Return on equity was 56.0% and debt-to-equity 0.66.
- Its Altman Z-score is 3.55 (safe zone) for fiscal 2025.